Evidence map›Paper›PMID 34837494›Full record

ArticleEuropean journal of clinical pharmacology2022

Automated multi-dose dispensing in persons with and without Alzheimer's disease-impacts on pharmacotherapy.

Sanna Vallius, Heidi Taipale, Marjaana Koponen, Anna-Maija Tolppanen, Antti Tanskanen, Sirpa Hartikainen, Miia Tiihonen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Multidose Drug Dispensing in Community Healthcare Settings for Patients With Multimorbidity and Polypharmacy.Inquiry : a journal of medical care organization, provision and financing
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sanna ValliusSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Heidi TaipaleSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Marjaana KoponenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Anna-Maija TolppanenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Antti TanskanenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Sirpa HartikainenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Miia TiihonenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland. miia.tiihonen@uef.fi.ORCID http://orcid.org/0000-0002-5069-5045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated the drug use before and after transition to automated multi-dose dispensing (MDD) service among persons with Alzheimer's disease (AD) and compared whether the changes were similar in persons without AD.

methodsThe register-based Finnish nationwide MEDALZ cohort includes 70,718 community-dwelling persons diagnosed with AD during 2005-2011. Each person who initiated MDD was matched in both groups with a comparison person without MDD by age, gender and for persons with AD, also time since AD diagnosis at the start of MDD. The study cohort included 15,604 persons with AD in MDD and 15,604 no-MDD, and 5224 persons without AD in MDD and 5224 no-MDD. Point prevalence of drug use was assessed every 3 months, from 1 year before to 2 years after the start of MDD and compared between persons in MDD to those who did not have MDD.

resultsMDD was started on average 2.9 (SD 2.1) years after AD diagnosis. At the start of MDD, the prevalence of drug use increased especially for antipsychotics, antidepressants, opioids, paracetamol and use of ≥ 10 drugs among persons with and without AD. Prevalence of benzodiazepine use (from 12% 12 months before to 17% at start of MDD), memantine (from 29 to 46%) and ≥ 3 psychotropics (from 3.2 to 6.0%) increased among persons with AD. Decreasing trend was observed for benzodiazepine-related drugs, urinary antispasmodics and non-steroidal anti-inflammatory drugs.

conclusionMDD seems to be initiated when use of psychotropics is initiated and the number of drugs increases.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesFemaleFinlandHumansMaleMedication SystemsMemantinePolypharmacyAntipsychotic AgentsBenzodiazepinesMemantineAlzheimer’s diseaseDementiaMulti-dose dispensingPolypharmacyPotentially inappropriate medicationsPsychotropic drugs

Identifiers

PMID34837494
PMCPMC8818643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.